Estonia vs Lebanon: Access to anti-retroviral drugs, female
Estonia
70.0%
in 2022
Lebanon
69.0%
in 2024
Estonia rank
82nd
Lebanon rank
84th
Access to anti-retroviral drugs, female over time
- Estonia
- Lebanon
How they compare
Estonia currently reports 70.0% against 69.0% in Lebanon, a difference of 1.0%.
The two have swapped places 2 times across 23 shared years of data; in 2000 it was Estonia ahead.
Estonia ranks 82nd and Lebanon ranks 84th of 141 countries.
Across the 3 decades both report, Estonia averaged higher in 2 and Lebanon in 1.
Head to head by decade
| Decade | Estonia | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.7% | 16.4% | 5.7% | Lebanon |
| 2010s | 57.8% | 42.5% | 15.3% | Estonia |
| 2020s | 71.7% | 66.3% | 5.3% | Estonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Estonia or Lebanon?
- Estonia, at 70.0% against 69.0% in Lebanon as of 2022.
- What is the difference in access to anti-retroviral drugs, female between Estonia and Lebanon?
- 1.0%, with Estonia ahead.
- How many years of comparable data are there for Estonia and Lebanon?
- 23 years are reported by both, from 2000 to 2022.
- How do Estonia and Lebanon rank globally for access to anti-retroviral drugs, female?
- Estonia ranks 82nd and Lebanon ranks 84th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.